

**TEST CHANGE**

**Clozapine and Metabolites, Serum or Plasma, Quantitative**

2013433, CLOZAP SP

**Specimen Requirements:**

**Patient Preparation:** Timing of specimen collection: Predose(trough) draw - at steady -state concentration.

**Collect:** Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2EDTA).

**Specimen Preparation:** Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP standard transport tube.(Min: 0.5 mL)

**Transport Temperature:** Refrigerated.

**Unacceptable Conditions:** Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).

**Remarks:**

**Stability:** After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 3 months

**Methodology:** Quantitative Liquid Chromatography-Tandem Mass Spectrometry

**Performed:** Sun-Sat

**Reported:** 1-5~~3~~ days

**Note:**

**CPT Codes:** 80159

**New York DOH Approval Status:** This test is New York DOH approved.

**Interpretive Data:**

Therapeutic ranges are not well established. Clozapine is metabolized to norclozapine and clozapine-N-oxide. Clozapine concentrations between 100 and 700 ng/mL may correlate more with clinical response; however, nonresponsiveness may also occur within this range. For refractory schizophrenia, clozapine concentrations greater than 350 ng/mL are suggested to achieve a therapeutic response.

**Toxicity:** Adverse effects to clozapine therapy may include tachycardia, drowsiness, hypotension, and seizures.

Therapeutic and toxic ranges are not well established in children.

Reference Interval:

Therapeutic Range	Not well established
Toxic Level	Total Clozapine and Metabolites: Greater than or equal to 1500 ng/mL